Northwest Biotherapeutics(NWBO)

Focus: Northwest Biotherapeutics is a public biotech company focused on dendritic cell immunotherapy for oncology indications, operating at pre-revenue scale with $2M annual revenue. The company is headquartered in Bethesda, MD and specializes in personalized cancer vaccines.

Oncology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Northwest Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Northwest Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$1M

Pipeline & Clinical Trials

DCVax-L

GBM

N/A

Clinical Trials (1)

NCT02146066Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

N/A

Help build intelligence for Northwest Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Two Phase 3 programs in glioblastoma and prostate cancer provide near-term clinical catalysts with meaningful upside potential
Pioneer position in dendritic cell immunotherapy offers deep scientific expertise and differentiated technology platform versus checkpoint inhibitor crowding
Public company status enables equity participation with liquidity and broader access to capital markets

Watch Out For

Severe cash burn ($62.6M net loss FY2024) against minimal revenue ($2M) creates existential sustainability risk without near-term Phase 3 success
No active hiring (0 open roles) signals organizational contraction and limited career mobility or team expansion opportunities
Extreme R&D intensity (1435%) with only 7 total clinical trials reflects resource constraints and execution risk

Generated by Claude from Northwest Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

DCVac-L

Ovarian Cancer

Phase 1

Clinical Trials (1)

NCT00683241A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

Phase 1

DCVax-Direct

Brain Metastases

Phase 1

Clinical Trials (1)

NCT03638765Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer

Phase 1

DCVax-Direct

Locally Advanced Tumor

Phase 1/2

Clinical Trials (1)

NCT01882946Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Phase 1/2

DCVax-L and T Cells

Ovarian Cancer

Phase 1/2

Clinical Trials (1)

NCT00603460DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

Phase 1/2

autologous dendritic cells pulsed with tumor lysate antigen Vaccine

Giant Cell Glioblastoma

Phase 2

Clinical Trials (1)

NCT03014804Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2

Dendritic cell immunotherapy

Prostate Cancer

Phase 3

Clinical Trials (1)

NCT00043212Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Phase 3

Dendritic cell immunotherapy

Glioblastoma Multiforme

Phase 3

Clinical Trials (1)

NCT00045968Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2017

Portfolio: 8 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$1M28%

R&D Spend

$35M(2524%)26%

Net Income

-$84M

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo